Keilah Ford
Psychiatric/Mental Health · Houston, TXNPI 1871980730
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 157 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 24 manufacturers, the largest accounting for just 17.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,514 and has fallen 59.1% since, to $619 in 2025.
Across 157 payments — averaging $24.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$691
- Otsuka America Pharmaceutical, Inc.$510
- Lundbeck LLC$291
- Sunovion Pharmaceuticals Inc.$273
- Alkermes, Inc.$228
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$225
- plus $2K from 18 others
What the payments were for
- Food & beverage$3,892100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 35 | $691 |
| Otsuka America Pharmaceutical, Inc. | 22 | $510 |
| Lundbeck LLC | 15 | $291 |
| Sunovion Pharmaceuticals Inc. | 15 | $273 |
| Alkermes, Inc. | 12 | $228 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 6 | $225 |
| Neurocrine Biosciences, Inc. | 11 | $201 |
| Teva Pharmaceuticals USA, Inc. | 9 | $191 |
| ARS Pharmaceuticals Operations, Inc. | 1 | $189 |
| Axsome Therapeutics, Inc. | 3 | $167 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $147 |
| Viiv Healthcare Company | 1 | $119 |
| Novo Nordisk | 1 | $107 |
| Corium, LLC | 4 | $106 |
| Lilly USA, LLC | 1 | $99 |
| Phadia US Inc. | 1 | $74 |
| Vanda Pharmaceuticals Inc. | 4 | $71 |
| Johnson & Johnson | 2 | $54 |
| Indivior Inc. | 2 | $44 |
| Eisai Inc. | 1 | $25 |
| Noven Therapeutics, LLC | 1 | $24 |
| Jazz Pharmaceuticals Inc. | 1 | $24 |
| Avanir Pharmaceuticals, Inc. | 1 | $21 |
| Almatica Pharma LLC | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,892 in reported general payments places this provider in the 85th percentile of 2,724 psychiatric/mental health providers in Texas.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 18 | $2,235 |
| Buspirone Hcl | 16 | $278 |
| Quetiapine Fumarate | 16 | $242 |
| Duloxetine Hcl | 17 | $148 |
Paid to pharmacies, not to this prescriber.
Other psychiatric/mental health in Houston
- Natalie TellezHouston$602K
- Britney PridgenHouston$57K
- Linzi LeightonHouston$16K
- Samantha SharpeHouston$14K
- Jennifer RobinsonHouston$12K
- Tracy HicksLongview$684K
- Karah BrashierRichardson$567K
- Grant DavisRichardson$360K
- Victor IlogEl Paso$167K
- Lisa ShamblinGrapevine$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.